Click here to watch the video version of this podcast.
Myopia has escalated to epidemic proportions with a global prevalence twice that of obesity. A study published in JAMA Ophthalmology in 2021 found the prevalence of myopia in six-year-old children in China jumped from 5.7% between 2015 and 2019 to 21.5% in 2020.
Given myopia affects about 40% of Americans and up to 90% of the East and Southeast Asians, it’s time to pick up the pace on education, treatment, and management.
At OIS XII in San Diego, a panel of experts discussed how the eye care community can make a difference in myopia within the pediatric population.
Moderated by David Kading, OD, of Specialty Eye in Seattle, Washington, the group discussed current FDA-approved and off-label treatments, as well as emerging solutions.
They also discussed the importance of raising parent awareness to reduce risk and progression of this disease.
Listen to the podcast today to hear the panelists discuss:
• What’s happening now in the myopia management space.
• Is myopia a disease?
• Exciting myopia developments coming in the next two to three years
• Steps to improve parent and patient education around myopia
• What it will take to significantly accelerate myopia treatment development and commercialization in the next five years
• Promising investment opportunities in myopia over the next five years
Robert A. Clark, MD—South Bay Family Eye/Associate Clinical Professor of Ophthalmology, Stein Eye Institute
Rajeev Garg, PhD—Global Head, Myopia Management Strategy, CooperVision
Matt Oerding—Board Member, GMAC/CEO & Co-Founder, Treehouse Eyes
David Kading, OD, FAAO, FCLSA—CEO, Specialty Eye (moderator)
Hit “Play” to Listen.